Sign in

PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer

By A. Santiago-Gomez and others at
LogoUniversity of Manchester
Despite the effectiveness of endocrine therapies to treat estrogen receptor-positive (ER+) breast tumours, two thirds of patients will eventually relapse due to de novo or acquired resistance to these agents. Cancer Stem-like Cells (CSCs), a rare cell population within the tumour, accumulate after anti-estrogen treatments and are likely to contribute... Show more
May 20, 2019
=
0
Loading PDF…
Loading full text...
Similar articles
Loading recommendations...
=
0
x1
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer
Click on play to start listening